Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy

Thyroid

Volumn 24, Issue 5, 2014, Pages 897-905

  Currò, Nicola ^a   Covelli, Danila ^a   Vannucchi, Guia ^a   Campi, Irene ^a   Pirola, Giacinta ^a   Simonetta, Simona ^a   Dazzi, Davide ^b   Guastella, Claudio ^a   Pignataro, Lorenzo ^a   Beck Peccoz, Paolo ^a   Ratiglia, Roberto ^a   Salvi, Mario ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b Ospedale di Fidenza   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID;

ADULT; AGED; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; COLOR SENSITIVITY; COLOR VISION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEPRESSION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; DYSPEPSIA; DYSTHYROID OPTIC NEUROPATHY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSIVE CRISIS; INSOMNIA; LOW DRUG DOSE; MALE; MYALGIA; OPTIC DISK; OPTIC NERVE DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TACHYCARDIA; THYROID DISEASE; VISUAL ACUITY; VISUAL FIELD; DECOMPRESSION SURGERY; DOSE RESPONSE; DRUG EFFECTS; DRUG PULSE THERAPY; DRUG RESISTANCE; FOLLOW UP; GRAVES OPHTHALMOPATHY; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OPTIC NERVE; PAPILLEDEMA; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; VISION;

ADMINISTRATION, INTRAVENOUS; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; COMBINED MODALITY THERAPY; DECOMPRESSION, SURGICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; OPTIC NERVE; PAPILLEDEMA; PULSE THERAPY, DRUG; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VISION, OCULAR;

EID: 84901267721     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0445     Document Type: Article

References (29)

1. Bahn RS 2010 Graves' ophthalmopathy. N Engl J Med 362:726-738.
2. Prummel MF, Bakker A, Wiersinga WM, Baldeschi L, Mourits MP, Kendall-Taylor P, Perros P, Neoh C, Dickinson AJ, Lazarus JH, Lane CM, Heufelder AE, Kahaly GJ, Pitz S, Orgiazzi J, Hullo A, Pinchera A, Marcocci C, Sartini MS, Rocchi R, Nardi M, Krassas GE, Halkias A 2003 Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: The first European Group on Graves' Orbitopathy experience. Eur J Endocrinol 148:491-495. (Pubitemid 36622154)
3. Lane CM, Boschi A 2010 Management of very severe Graves' orbitopathy (dysthyroid optic neuropathy and corneal breakdown). In: Wiersinga WM, Kahaly GJ (eds) Graves' Orbitopathy: A Multidisciplinary Approach. Second edition. Karger, Basel, pp. 153-159.
4. McKeag D, Lane C, Lazarus JH, Baldeschi L, Boboridis K, Dickinson AJ, Hullo AI, Kahaly G, Krassas G, Marcocci C, Marino M, Mourits MP, Nardi M, Neoh C, Orgiazzi J, Perros P, Pinchera A, Pitz S, Prummel MF, Sartini MS, Wiersinga WM 2007 Clinical features of dysthyroid optic neuropathy: A European Group on Graves' Orbitopathy (EUGOGO) survey. Br J Ophthalmology 91:455-458.
5. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas G, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM 2008 Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid 18:333-346. (Pubitemid 351415802)
6. Lucarelli MJ, Shore JW 1996 Management of thyroid optic neuropathy. Int Ophthalmol Clin 36:179-193. (Pubitemid 26116953)
7. Soares-Welch CV, Fatourechi V, Bartley GB, Beatty CW, Gorman CA, Bahn RS, Bergstralh EJ, Schleck CD, Garrity JA 2003 Optic neuropathy of Graves' disease: Results of transantral orbital decompression and long-Term follow-up in 215 patients. Am J Ophthalmol 136:433-441. (Pubitemid 37101239)
8. Milligan NM, Newcombe R, Compston DAS 1987 A double blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: Clinical effects. J Neurol Neurosurg Psychiatry 50:511-516. (Pubitemid 17067536)
9. Cleary PA, Beck RW, Anderson MM Jr, Kenny DJ, Backlund JY, Gilbert PR 1993 Design, methods, and conduct of the Optic Neuritis Treatment Trial. Control Clin Trials 14:123-142. (Pubitemid 23102301)
10. Guy JR, Fagien S, Donovan JP, Rubin ML 1989 Methylprednisolone pulse therapy in severe disthyroid optic neuropathy. Ophthalmology 96:1048-1053. (Pubitemid 19182149)
11. Mourits MP, Kalman R, Sasim IV 2001 Methylprednisolone pulse therapy for patients with dysthyroid optic neuropathy. Orbit 20:275-280. (Pubitemid 34098645)
12. Wakelkamp IM, Baldeschi L, Saeed P, Mourits MP, Prummel MF, Wiersinga WM 2005 Surgical or medical decompression as first line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clin Endocrinol 63:323-328. (Pubitemid 41233451)
13. The European Group on Graves' Orbitopathy (EUGOGO): Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, Boboridis K, Boschi A, Dickinson AJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marino M, Nardi M, Neoh C, Orgiazzi J, Pinchera A, Pitz S, Prummel MF, Sartini MS, Stahl M, von Arx G 2006 Clinical assessment of patients with Graves' orbitopathy: The European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. European Journal of Endocrinology 155:387-389.
14. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, Van Der Gaag 1989 Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: A novel approach. Br J Ophthalmol 73:639-644.
15. Nagayama Y, Izumi M, Kiriyama T, Yokoyama N, Morita S, Kakezono F, Ohtakara S, Morimoto I, Okamoto S, Nagataki S 1987 Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy. Acta Endocrinol 116:513-518. (Pubitemid 17163691)
16. Kendall-Taylor P, Crombie AL, Stephenson AM, Hardwick M, Hall K 1988 Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy. Br Med J 297:1574-1578. (Pubitemid 19002701)
17. Tagami T, Tanaka K, Sugawa H, Nakamura H, Miyoshi Y, Mori T, Nakao K 1996 High dose intravenous steroid pulse therapy in thyroid associated ophthalmopathy. Endocr J 43:689-699. (Pubitemid 126447904)
18. Matejka G, Verges B, Vaillant G Petit JM, Brun-Pacaud A, Rudoni S, Brun JM 1996 Intravenous methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy. Horm Metab Res 30:93-98.
19. Zang S, Ponto KA, Kahaly GJ 2011 Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: Efficacy and morbidity. J Clin Endocrinol Metab 96:320-332.
20. Kahaly GJ, Pitz S, Hommel G, Dittmar M 2005 Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 90:5234-5240. (Pubitemid 41262280)
21. Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Veronesi G, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Currò N, Boschi A, Bernard M, von Arx G; European Group on Graves' Orbitopathy 2012 Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. J Clin Endocrinol Metab 97:4454-4463.
22. Panzo GJ, Tomsak RL 1983 A retrospective review of 26 cases of dysthyroid optic neuropathy. Am J Ophthalmol 96:190-194. (Pubitemid 13037293)
23. Ben Simon GJ, Syed HM, Douglas R, Schwartz R, Goldberg RA, McCann JD 2006 Clinical manifestation and treatment outcome of optic neuropathy in thyroid related orbitopathy. Ophthalmic Surg Lasers Imaging 37: 284-290. (Pubitemid 44166240)
24. Hart RH, Kendall-Taylor Pat, Crombie A, Perros P 2005 Early response to intravenous glucocorticoids for severe Thyroid associated ophthalmopathy predicts treatment outcome. J Ocul Pharmacol Ther 21:328-336. (Pubitemid 41192904)
25. Marinó M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marocci C 2004 Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 14: 403-406. (Pubitemid 38756663)
26. Le Moli R, Baldeschi L, Saeed P Regensburg N, Mourits MP, Wiersinga WM 2007 Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy. Thyroid 17:357-362. (Pubitemid 46776141)
27. Salvi M, Vannucchi G, Sbrozzi F, Del Castello AB, Carnevali A, Fargion S, Beck-Peccoz P 2004 Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-Associated ophthalmopathy in a patient with Hashimoto's thyroiditis: Case report. Thyroid 14:631-634. (Pubitemid 39097088)
28. Liao SL, Chang TC, Lin LL. 2006 Transcaruncular orbital decompression: An alternate procedure for Graves ophthalmopathy with compressive optic neuropathy. Am J Ophthalmol 141:810-818.
29. Choe CH, Cho RI, Elner VM. 2011 Comparison of lateral and medial orbital decompression for the treatment of compressive optic neuropathy in thyroid eye disease. Ophthal Plast Reconstr Surg 27:4-11.